Published in Medicine and Law Weekly, September 8th, 2006
Avi licensed its vascular disease program to the Cook Group, Inc., (Cook) in March 2006 for device delivery of the NeuGene antisense drug Avi-4126, while the company is focusing internal development on coronary artery bypass graft (CABG) using Avi-5126. The following patents were the subject of the U.S. Patent Office's notification:
"Antisense Restenosis Composition and Method" covers the broad use of Avi-4126 to treat any vascular injury including balloon...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.